# AcornMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acornmed

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.acornmed.com
- Total disclosed funding: $43M
- Latest round: Series B (Dec 27, 2022)
- Investors on record: 8

## About

Based in Beijing, China, and established in 2018, AcornMed is a biotechnology company that focuses on cancer gene testing services and medical equipment and has test R&D centers in Beijing and Tianjin. It owns approximately 100 invention patents and software copyrights. Moreover, it established cooperation with MGI Tech. Co. Ltd., Huawei Cloud, Twist Bioscience, AZN, and Roche. More than 80% of the technical personnel have masters or doctoral degrees.

AcornMed provides 40 gene test products for solid tumors and hematological tumors including 20 gene test products that received CE certification. The gene test products for solid tumors include lung cancer, rectal cancer, and urological tumors. It also established gene data databases, which include over 100,000 cancer patients' genomic data.

## Funding rounds

- Series B, Dec 27, 2022, $29M — Elikon Venture, Yikai Ventures, Qingdao Hongteng, Wushi Capital
- Series A, Jan 1, 2020, $14M — Sino-Ocean Capital, Yushan Partners, Lingxian Jiankang, Yingdi Capital

## Investors

- Sino-Ocean Capital (https://capitalatlas.ai/funds/sino-ocean-capital) — Series A
- Yushan Partners (https://capitalatlas.ai/funds/yushan-partners) — Series A
- Lingxian Jiankang — Series A
- Yingdi Capital — Series A
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series B
- Yikai Ventures — Series B
- Qingdao Hongteng — Series B
- Wushi Capital — Series B